{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:44:32Z","timestamp":1789789472590,"version":"4.0.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI123036 and R01AI173238"],"award-info":[{"award-number":["P01 AI123036 and R01AI173238"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      resistance to standard-of-care agents is increasing. It is imperative to identify new combinations that increase the rate and depth of bacterial kill, shorten therapy and also suppress resistance. There has been little prior effort to identify combination regimens that employ new or repurposed drugs in a rational way.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and Findings<\/jats:title>\n                    <jats:p>\n                      Our group developed a pathway to combine agents to achieve this end. This pathway starts with standard baseline evaluations (e.g., MIC), leverages information from\n                      <jats:italic>in vitro<\/jats:italic>\n                      assessments (hollow fiber infection model), then analyzes 2-agent combinations in a 96 well quantitative culture checkerboard format (Greco URSA model with simulation). Finally, development of a high dimensional mathematical model allowed evaluation of 2- and 3-drug regimens in multiple metabolic states to draw inferences regarding combination therapies. We prospectively evaluated these regimens in animal models. We showed that a prospectively chosen regimen of pretomanid, moxifloxacin plus bedaquiline performed as predicted. In the BALB\/c murine model, this regimen produced sterilization in a cohort that was held for 12 weeks after therapy cessation, as it did in the C3HeB\/FeJ (\u201cKramnik\u201d) murine model. Finally, this and other regimens were evaluated in a cynomolgus macaque model. The decrement of the\n                      <jats:sup>18<\/jats:sup>\n                      F-deoxyglucose signal in Positron emission tomography (PET)- computed tomography (CT) evaluations was best with this regimen. Other endpoints such as necropsy score and colony counts in lung and lymph nodes also demonstrated that this regimen behaved as predicted from our pathway\/algorithm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We conclude that this provides a way forward for the future to identify the most promising regimens to shorten therapy for tuberculosis and suppress emergence of resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0324206","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:38:03Z","timestamp":1770748683000},"page":"e0324206","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations"],"prefix":"10.1371","volume":"21","author":[{"given":"Arnold","family":"Louie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0735","authenticated-orcid":true,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Scanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnne L.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":true,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Prideaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almoslem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3512-9202","authenticated-orcid":true,"given":"Walter","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-7332","authenticated-orcid":true,"given":"George","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"pone.0324206.ref001","volume-title":"Global tuberculosis report 2020","author":"World Health Organization","year":"2020"},{"issue":"10325","key":"pone.0324206.ref002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pone.0324206.ref003","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s11033-024-10014-9","article-title":"Prevalence of rifampicin and isoniazid mono-resistance among cases of pulmonary tuberculosis from Western Uttar Pradesh, North India","volume":"51","author":"R Kumar","year":"2024","journal-title":"Mol Biol Rep"},{"issue":"10","key":"pone.0324206.ref004","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1513\/AnnalsATS.202312-1076OC","article-title":"The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa","volume":"21","author":"M Klopper","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"pone.0324206.ref005","doi-asserted-by":"crossref","first-page":"20401","DOI":"10.1038\/s41598-024-70199-8","article-title":"Drug resistance and genomic variations among Mycobacterium tuberculosis isolates from the Nile Delta, Egypt","volume":"14","author":"MS Soliman","year":"2024","journal-title":"Scientific Reports"},{"key":"pone.0324206.ref006","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2024.05.018","article-title":"Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China: A systematic review and meta-analysis","volume":"38","author":"C Jin","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"pone.0324206.ref007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"SE Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"pone.0324206.ref008","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"SH Gillespie","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0324206.ref009","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.accounts.0c00878","article-title":"Strategies to Combat Multi-Drug Resistance in Tuberculosis","volume":"54","author":"V Singh","year":"2021","journal-title":"Acc Chem Res"},{"issue":"12","key":"pone.0324206.ref010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01376-20","article-title":"Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?","volume":"64","author":"GL Drusano","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0324206.ref011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02172-20","article-title":"The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens","volume":"65","author":"GL Drusano","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0324206.ref012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01610-20","article-title":"Building Optimal Three-Drug Combination Chemotherapy Regimens","volume":"64","author":"GL Drusano","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0324206.ref013","article-title":"Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase","volume":"65","author":"S Kim","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0324206.ref014","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00695-22","article-title":"Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype","volume":"66","author":"W Yamada","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pone.0324206.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101311","article-title":"Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis","volume":"9","author":"GL Drusano","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"pone.0324206.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01470-18","article-title":"Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model","volume":"62","author":"A Louie","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0324206.ref017","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"T Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0324206.ref018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00856-18","article-title":"Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay","volume":"62","author":"C de Miranda Silva","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0324206.ref019","volume-title":"Susceptibility testing of Mycobacteria, Nocardia spp., and other aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute","year":"2020"},{"issue":"6","key":"pone.0324206.ref020","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"S Tyagi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0324206.ref021","article-title":"Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis","volume":"63","author":"J Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0324206.ref022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2003.07.001","article-title":"The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates","volume":"49","author":"JM Hartings","year":"2004","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"9","key":"pone.0324206.ref023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00788-17","article-title":"Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model","volume":"61","author":"HS Heine","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0324206.ref024","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.36.3.548","article-title":"Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice","volume":"36","author":"J Grosset","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0324206.ref025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"EL Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0324206.ref026","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"ER Driver","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0324206.ref027","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fimmu.2012.00411","article-title":"The granuloma in tuberculosis: dynamics of a host-pathogen collusion","volume":"3","author":"S Ehlers","year":"2013","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0324206.ref028","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1242\/dmm.019570","article-title":"Presence of multiple lesion types with vastly different microenvironments in C3HeB\/FeJ mice following aerosol infection with Mycobacterium tuberculosis","volume":"8","author":"SM Irwin","year":"2015","journal-title":"Dis Model Mech"},{"issue":"4","key":"pone.0324206.ref029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB\/FeJ Mice","volume":"2","author":"SM Irwin","year":"2016","journal-title":"ACS Infect Dis"},{"issue":"11","key":"pone.0324206.ref030","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177427","article-title":"Intermittent glucocorticoid treatment improves muscle metabolism via the PGC1\u03b1\/Lipin1 axis in an aging-related sarcopenia model","volume":"134","author":"AD Prabakaran","year":"2024","journal-title":"J Clin Invest"},{"issue":"6","key":"pone.0324206.ref031","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jimmun\/vkaf038","article-title":"Cryptococcosis, tuberculosis, and a kidney cancer fail to fit the atherosclerosis paradigm for foam cell lipid content","volume":"214","author":"V Guerrini","year":"2025","journal-title":"J Immunol"},{"key":"pone.0324206.ref032","first-page":"56375","article-title":"Analysis of 18FDG PET\/CT imaging as a tool for studying Mycobacterium tuberculosis infection and treatment in non-human primates","volume":"127","author":"AG White","year":"2017","journal-title":"J Vis Exp"},{"issue":"9","key":"pone.0324206.ref033","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1128\/AAC.00277-13","article-title":"Radiologic Responses in Cynomolgus Macaques for Assessing Tuberculosis Chemotherapy Regimens","volume":"57","author":"PL Lin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"265","key":"pone.0324206.ref034","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009500","article-title":"PET\/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis","volume":"6","author":"MT Coleman","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"pone.0324206.ref035","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"R Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pone.0324206.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"D Almeida","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0324206.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00139-10","article-title":"The combination of rifampin plus moxifloxacin is synergistic for resistance suppression but is antagonistic for cell kill for Mycobacterium tuberculosis as determined in a hollow fiber infection model","volume":"1","author":"GL Drusano","year":"2010","journal-title":"mBio"},{"issue":"8","key":"pone.0324206.ref038","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00221-18","article-title":"Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model","volume":"62","author":"GL Drusano","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0324206.ref039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02533-20","article-title":"Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression","volume":"65","author":"GL Drusano","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0324206.ref040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"10","key":"pone.0324206.ref041","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1128\/AAC.00821-10","article-title":"Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis","volume":"54","author":"C Sala","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0324206.ref042","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/AAC.01125-12","article-title":"Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis","volume":"56","author":"M Zhang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0324206.ref043","first-page":"273","article-title":"The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus pas","volume":"31","author":"JB Selkon","year":"1964","journal-title":"Bull World Health Organ"},{"issue":"2","key":"pone.0324206.ref044","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-3879(73)90031-7","article-title":"Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council","volume":"54","year":"1973","journal-title":"Tubercle"},{"issue":"15","key":"pone.0324206.ref045","doi-asserted-by":"crossref","first-page":"8560","DOI":"10.1073\/pnas.150227197","article-title":"Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis","volume":"97","author":"I Kramnik","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pone.0324206.ref046","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jir786","article-title":"Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions","volume":"205","author":"J Harper","year":"2012","journal-title":"J Infect Dis"},{"issue":"12","key":"pone.0324206.ref047","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acsinfecdis.9b00207","article-title":"Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis","volume":"5","author":"AA Ordonez","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"6","key":"pone.0324206.ref048","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/ac1029049","article-title":"High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions","volume":"83","author":"B Prideaux","year":"2011","journal-title":"Anal Chem"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:38:12Z","timestamp":1770748692000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324206"}},"subtitle":[],"editor":[{"given":"Satish","family":"Rojekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324206","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}